GlaxoSmithKline has entered an agreement to acquire Reliant Pharmaceuticals Inc. for $1.65 billion in cash. Reliant is a privately held specialty pharma company focused on cardiovascular therapies. In the nine months ending September 30, 2007, the company’s net sales were $341 million, up 62% YTD. Through its strategic in-licensing strategy, Reliant has developed a portfolio of specialty drugs for heart disease, including U.S. rights to Lovaza, a treatment for adult patients with very...